Literature DB >> 1155449

Heterogeneity for adenosine deaminase deficiency: Expression of the enzyme in cultured skin fibroblasts and amniotic fluid cells.

S H Chen, C R Scott, D R Swedberg.   

Abstract

Adenosine deaminase (ADA) could be quantitated and the isozyme pattern characterized in cultured amniotic fluid cells. In 20 amniotic fluid cell cultures the mean specific activity was 14.3 U/g protein +/- 6.7 (SD) and compared favorably with values of 14.6 U/g protein +/- 6.8 (SD) observed in 26 cultures of skin fibroblasts. In cultures of skin fibroblasts established from two obligate heterozygotes for ADA deficiency, the specific activity of ADA was 7.0 and 7.7 U/g protein. The ADA isozyme pattern that existed in cultures of amniotic fluid cells was the same as that observed in cultured skin fibroblasts. This identification of the same apparent enzyme may permit the prenatal diagnosis of that form of combined immunodeficiency disease caused by ADA deficiency. Residual enzyme activity of less than 1% and 10% of the mean of normal fibroblasts could be measured in cultured fibroblasts from two unrelated children with ADA deficiency and combined immunodeficiency disease. The tissue-specific enzyme from cultured skin fibroblasts from the child with 10% residual activity had a faster electrophoretic mobility and greater heat stability than normal ADA. This enzymatic evidence indicates that at least two mutant alleles exist at the locus for ADA which predispose to combined immunodeficiency disease when present in the homozygous state.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155449      PMCID: PMC1762767     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Letter: Severe combined immunodeficiency and adenosine-deaminase deficiency.

Authors:  R Hirschhorn; N G Beratis
Journal:  Lancet       Date:  1973-11-24       Impact factor: 79.321

3.  Letter: Autosomal assignment of the gene for the form of adenosine deaminase which is deficient in patients with combined immunodeficiency syndrome.

Authors:  R P Creagan; J A Tischfield; E A Nichols; F H Ruddle
Journal:  Lancet       Date:  1973-12-22       Impact factor: 79.321

4.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

5.  Evidence for control of several different tissue-specific isozymes of adenosine deaminase by a single genetic locus.

Authors:  R Hirschhorn; V Levytaka; B Pollara; H J Meuwissen
Journal:  Nat New Biol       Date:  1973-12-19

6.  Adenosine deaminase: demonstration of a "silent" gene associated with combined immunodeficiency disease.

Authors:  S H Chen; R Scott; E R Giblett
Journal:  Am J Hum Genet       Date:  1974-01       Impact factor: 11.025

7.  Adenosine deaminases of two different molecular sizes in human tissues.

Authors:  H Akedo; H Nishihara; K Shinkae; K Komatsu
Journal:  Biochim Biophys Acta       Date:  1970-07-15

8.  Adenosine deaminase isozymes in human tissues.

Authors:  Y H Edwards; D A Hopkinson; H Harris
Journal:  Ann Hum Genet       Date:  1971-10       Impact factor: 1.670

9.  Detection of the carrier state in combined immunodeficiency disease associated with adenosine deaminase deficiency.

Authors:  C R Scott; S H Chen; E R Giblett
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

10.  Further data on the adenosine deaminase (ADA) polymprphism and a report of a new phenotype.

Authors:  D A Hopkinson; P J Cook; H Harris
Journal:  Ann Hum Genet       Date:  1969-05       Impact factor: 1.670

View more
  15 in total

1.  Adenosine deaminase activity in erythrocytes, lymphocytes, polymorphonuclear neutrophil leucocytes and cultured cells: a possible role in the immune response.

Authors:  A Adams; R A Harkness; J G McVie
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

2.  Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency.

Authors:  W P Schrader; B Pollara; H J Meuwissen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

Authors:  P E Daddona; B S Mitchell; H J Meuwissen; B L Davidson; J M Wilson; C A Koller
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

4.  Purine nucleoside phosphorylase deficiency. Measurement of variant protein in four families with enzyme-deficient members by an enzyme-linked immunosorbent assay.

Authors:  W R Osborne; C R Scott
Journal:  Am J Hum Genet       Date:  1980-11       Impact factor: 11.025

5.  Use of genetic markers to certify fetal origin of cultured amniotic fluid cells.

Authors:  S H Chen; L E Karp; C R Scott; W Chen
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

6.  Prenatal diagnosis for adenosine deaminase deficiency.

Authors:  J B Ziegler; M B Van der Weyden; C H Lee; A Daniel
Journal:  J Med Genet       Date:  1981-04       Impact factor: 6.318

7.  Antenatal diagnosis of Krabbe's leucodystrophy: enzymatic and morphological confirmation in an affected fetus.

Authors:  D F Farrell; S M Sumi; C R Scott; G Rice
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-01       Impact factor: 10.154

Review 8.  Analysis of normal and mutant forms of human adenosine deaminase - a review.

Authors:  P E Daddona; W N Kelley
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

9.  Expression of human adenosine deaminase after fusion of adenosine deaminase-deficient cells with mouse fibroblasts.

Authors:  M J Siciliano; M R Bordelon; P O Kohler
Journal:  Proc Natl Acad Sci U S A       Date:  1978-02       Impact factor: 11.205

10.  A normal level of adenosine deaminase activity in the red cell lysates of carriers and patients with severe combined immunodeficiency disease.

Authors:  P P Trotta; E M Smithwick; M E Balis
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.